2013 |
Chronic Dry Eye Disease is Principally Mediated by Effector Memory Th17 Cells 4
|
Effector memory Th17 cells are primarily responsible for maintaining the chronic and relapsing course of DED |
2012 |
Dry Eye Disease: An Immune-Mediated Ocular Surface Disorder 78
|
Fundamental links between inflammation and dry eye disease. |
2012 |
Efficacy of Topical Blockade of Interleukin-1 in Experimental Dry Eye Disease 79
|
Topical treatment with IL-1Ra is effective in ameliorating the clinical signs of the dry eye disease as well as in reducing underlying inflammation. |
2012 |
Expression of Toll-Like Receptor 4 Contributes to Corneal Inflammation in Experimental Dry Eye Disease 80
|
DED increases the corneal expression of TLR4 and that TLR4 participates in the inflammatory response to ocular surface desiccating stress. |
2012 |
Ocular Surface Immunity: Homeostatic Mechanisms and Their Disruption in Dry Eye Disease 81
|
Disruption of afferent and efferent immune regulatory mechanisms are responsible for the chronicity of the disease, its symptoms, and its clinical signs. |
2011 |
Interferon-Gamma-Secreting NK Cells Promote Induction of Dry Eye Disease 82
|
IFN-γ-secreting NK cells can promote induction of DED via direct target tissue damage and indirect influence on the priming phase of an adaptive immune response in secondary lymphoid tissue. |
2011 |
Therapeutic Efficacy of Topical Epigallocatechin Gallate in Murine Dry Eye 83
|
Topical EGCG treatment is able to reduce the clinical signs and inflammatory changes in DED by suppressing the inflammatory cytokine expression and infiltration of CD11b+ cells in the cornea. |
2010 |
Evidence of Corneal Lymphangiogenesis in Dry Eye Disease A Potential Link to Adaptive Immunity? 84
|
Low-grade inflammation associated with DED is an inducer of lymphangiogenesis without accompanying hemangiogenesis. |
2009 |
Autoimmunity in Dry Eye Is Due to Resistance of Th17 to Treg Suppression 85
|
Pathogenic T cell subset (Th17) in DED is associated specifically with Treg dysfunction and disease pathogenesis . |
2009 |
Amelioration of Murine Dry Eye Disease by Topical Antagonist to Chemokine Receptor 2 86
|
Topical application of CCR2 antagonist is associated with significant improvement in dry eye disease and is reflected by a decrease in inflammation at the clinical, molecular, and cellular levels. |